跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 41 条关于
“Cas12”
全部
41
临床试验
4
药物
8
机构
0
资讯
29
3年前
CRISPR Gene Therapies Show Promise in Early Sickle Cell Disease Trials
去年
VedaBio Secures $40M Series A and Strategic Partnership with Siemens Healthineers for CRISPR Diagnostics Platform
7天前
Editas Medicine Targets 2026 Patient Dosing for In Vivo CRISPR LDL Therapy EDIT-401
去年
China's Biopharma Sector Showcases Innovation Leadership at BIOSeedin 2025 Conference
2年前
FDA Clears IND for Arbor Biotechnologies' ABO-101 Gene-Editing Therapy for Primary Hyperoxaluria Type 1
去年
Federal Circuit Remands CRISPR Patent Dispute to PTAB in Ongoing Editas Medicine Case
11天前
tBE Base Editing Therapy Achieves Durable Remission in Sickle Cell Disease and β-Thalassemia Across Diverse Genetic Backgrounds
去年
CRISPR Weekly Roundup: Advancements in Gene Editing and Clinical Trials
去年
Arbor Biotechnologies' ABO-101 Receives FDA Clearance for Phase 1/2 Trial in Primary Hyperoxaluria Type 1
去年
YolTech's YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 with Positive Clinical Data
第 1 页,共 3 页
上一页
下一页